Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) traded down 49.5% during mid-day trading on Tuesday . The stock traded as low as $2.02 and last traded at $2.02. 400 shares changed hands during trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Trading Down 49.5 %
The company’s fifty day moving average price is $2.02 and its 200-day moving average price is $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Articles
- Five stocks we like better than H-CYTE
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- Stock Market Sectors: What Are They and How Many Are There?
- Netflix Is On Track To Hit $1,000 By Christmas
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
